The Gift from 'Little Pearl Harbor'
Source: Ray Blanco, The Daily Reckoning  (8/10/12)
"A smart acquisition that can be commercialized quickly can start generating sales in a fraction of the time. . .and that is what is happening today." More >

Health Care Law's Tax Hikes Are Coming: Who Pays?
Source: Associated Press, Connie Cass  (8/10/12)
"The wealthiest 2% of Americans will take the biggest hit, starting next year. And the pain will be shared by some who aren't so well off—people swept up in a hodgepodge of smaller tax changes that will help finance health coverage for millions in need." More >

Think Long Term and Win Big with Small Biotechs: Hugh Cleland
Source: George S. Mack of The Life Sciences Report  (8/9/12)
BluMont Capital Portfolio Manager Hugh Cleland has taken a venture capital and private equity approach to investing in public companies, some of which have penny-stock market caps in the $5–15 million range. The idea is to invest in small- and micro-cap stocks without facing redemption risk, and to employ a hands-on approach when helping innovative companies create and realize value over the long term. In this way time becomes the friend—not the enemy—of companies looking for scarce capital in a risk-averse world. In this exclusive interview with The Life Sciences Report, Cleland shares the names of a handful of small companies that could return tenfold or greater multiples to investors. More >

Lilly Raises Profit Forecast on Amylin's $1.26B Payment
Source: Reuters, Toni Clarke and Esha Dey  (8/9/12)
"Lilly plans to use the cash to advance its 'pipeline of more than 60 potential new medicines,' among other corporate uses." More >

Battles over FDA Use Code Challenge Branded Drug Exclusivity
Source: Isabelle Blundell, Genetic Engineering and Biotechnology News  (8/9/12)
"Successful marketing of pharmaceutical drugs can be put at risk if FDA approval is not carefully conducted in parallel patent issuance." More >

The Phytochemical and Nutraceutical Revolution Starts Right Now
Source: Patrick Cox, The Penny Sleuth   (8/8/12)
"As investors, we have a huge opportunity to invest in early-stage, revolutionary companies working on plant- and animal-based health solutions that bypass the lengthy and extremely expensive FDA approval process." More >

How to Cure Aging, Disease and Low Stock Performance
Source: Patrick Cox, The Penny Sleuth  (8/6/12)
"To live a longer and wealthier life, now's the time to add companies with inflammation-beating products to your medicine cabinet and your portfolio." More >

Disruptive Biotechnologies Stir Up Profits: Ray Blanco
Source: George S. Mack of The Life Sciences Report  (8/2/12)
As coeditor of Technology Profits Confidential and contributor to Breakthrough Technology Alert and Penny Sleuth at Agora Financial, Ray Blanco searches far and wide for breakthrough ideas and disruptive technologies that will change the lives of very sick patients. In this exclusive interview with The Life Sciences Report, Blanco discusses how investors can reap big gains with biotech companies that possess disease-busting platforms but are not yet fully valued by the markets. More >

Biotech M&A at Four-Year High as Pharma Faces Expiring Patents
Source: Reuters, Soyoung Kim and Paritosh Bansal  (8/2/12)
"Big pharma's preference for commercial-stage assets, rather than clinical trial-stage drugs carrying regulatory approval risk, means that companies tend to pursue multibillion-dollar transactions rather than going for smaller deals." More >

The Quiet Outperformance of Recent Biotech IPOs
Source: Forbes, Bruce Booth  (8/1/12)
"New biotech IPOs have quietly been putting points on the board with their post-IPO performance. It's now fair to say they have resoundingly outperformed their tech cousins in the public markets." More >

New Hope for Alzheimer's Disease
Source: Gail Dutton, Genetic Engineering & Biotechnology News  (8/1/12)
"Optimism has been fostered by the more than 150 firms working in Alzheimer's pace and the countless approaches being explored." More >

Dendreon to Close New Jersey Plant, Cut 600 Jobs
Source: Reuters  (7/30/12)
"The company, whose Provenge treatment for prostate cancer has had disappointing sales since it was launched in April 2010, and which is facing growing competition from easier-to-administer drugs, said the closure of its Morris Plains, New Jersey, factory would greatly reduce its cost of goods sold." More >

Brains Are Different in People with Highly Superior Autobiographical Memory
Source: Science Daily   (7/30/12)
"UC Irvine scientists have discovered intriguing differences in the brains and mental processes of an extraordinary group of people who can effortlessly recall every moment of their lives since about age 10." More >

Fascinating New Technology Trends Offer a Glimpse into a Wild Future
Source: Michael Robinson, Money Morning  (7/27/12)
"Cutting-edge high tech is moving at warp speed, with new advances coming faster than any one person can track." More >

Immunotherapies Attack Cancers and Grow Portfolios: Mara Goldstein
Source: George S. Mack of The Life Sciences Report   (7/26/12)
Sometimes valuations don't match the fundamentals of a stock, according to Cantor Fitzgerald & Co. Senior Biotechnology Analyst Mara Goldstein, who understands the science and its relationship to value. Goldstein recommends a handful of small-cap immunotherapy companies that were up 14–42% over the month of June; she also has one large-cap idea for more patient investors. In this exclusive interview with The Life Sciences Report, Goldstein makes a case for favorite companies that should continue making shareholders happy. More >

Special Report Reveals Biotech Stock Drivers: Michael Hay
Source: George S. Mack of The Life Sciences Report  (7/26/12)
Certain predictable dates and events bring profound effects to bear on biotech stocks. Michael Hay, vice president of Sagient Research Systems, successfully applies the art and science of important catalysts to predict when biotech stocks will move up or down. In this exclusive interview with The Life Sciences Report, Hay discusses his strategy and names companies that will produce meaningful gains for investors. More >

Good News in Hard Times: More Money for Biopharma
Source: Genetic Engineering & Biotechnology News  (7/26/12)
"Venture capital firm New Enterprise Associates says investments in biopharma and other healthcare startups will be included in its just-closed 14th fund totaling $2.6B." More >

Six Ways to Save Biotech
Source: BioSpace, Karl Thiel  (7/24/12)
"Of course, the number one way to return the biotech ecosystem to full health is to build a healthy economy in which there is more appetite for risk. But let's hope the current adversity will lead to some creativity that will better serve the industry in good times as well as bad." More >

Three Important Biotech Names
Source: George S. Mack, The Life Sciences Report  (7/21/12)
The term reovirus (respiratory enteric orphan virus) was originated by Albert Sabin, who is now synonymous with the oral poliomyelitis vaccine that bears his name. Now, after more than a half-century of research, investigators at a handful of biotech companies are moving the virus forward as a cancer-fighting agent. The reovirus is found extensively in nature, and most humans have had a GI tract infection with it by the time they are beyond childhood or into early adulthood. Reovirus infection is in most cases asymptomatic, and it is not at all considered to be virulent. So, what meaning does a harmless virus have for disease, and especially for deadly cancers? More >

Fewer Approvals and Filings Sully FDA Offensive
Source: Alex Philippidis, Genetic Engineering & Biotechnology News  (7/20/12)
"Despite declines in the first half of 2012, FDA remains on track to roughly replicate its performance for all last year, when 30 new drugs won approvals." More >

Biotech 'Diamonds-in-the-Rough' Promise Huge Potential Returns: Rahul Jasuja
Source: George S. Mack of The Life Sciences Report   (7/19/12)
Rahul Jasuja, managing director and senior biotechnology analyst with Noble Financial Capital Markets, doesn't shy away from the smallest micro-cap companies. He relishes the potential upside in finding undervalued drug developers with technology platforms that are, frankly, difficult for most investors to understand. The micro-cap companies he covers must demonstrate scientific rigor and have management capable of executing corporate and clinical goals. In this exclusive interview with The Life Sciences Report, Jasuja shares some of his favorite names, which he believes can return major multiples back to investors. More >

Why Your Health Care Is So Darn Expensive
Source: Alex Daley and Doug Hornig, Casey Research  (7/19/12)
"At that point, it isn't lifestyle changes that are keeping us alive—it's machines and doctors and medicines doing a lot of the heavy lifting in order to grant us those precious extra days." More >

Mergers Show How Affordable Care Act Will Deliver Profits
Source: Don Miller, Money Morning  (7/19/12)
"The two largest managed care firms, UnitedHealth Group Inc. and WellPoint, are now big players in Medicare Advantage and Medicaid, according to The Huffington Post. And with the impending influx from the Affordable Care Act, they plan to get even bigger." More >

Personalized Medicine: Challenges Lie Ahead
Source: John Sterling, Genetic Engineering and Biotechnology News  (7/18/12)
"'The beautiful thing about personalized medicine is we're going to mitigate the technical risk dramatically. . .But until we solve the business model question, we have a significant challenge.'–Dr. David Nelson." More >

Four Ways to Outrun Obsolescence in Biotech
Source: Zachary N. Russ, Genetic Engineering and Biotechnology News  (7/17/12)
"To stay ahead in the ever-quickening world of research, scientists must be fast and cunning." More >